Thank you to our Speakers, Sponsors & Delegates for joining us!
Register your interest to be the first to hear updates about the 2025 meeting.
Welcome to the 3rd Next Generation RNA Therapeutics Summit
Pioneering the Next Breakthrough in Durable & Potent Circular RNA, Transfer RNA, Self-Amplifying RNA Therapeutics for Patients in Need
As the field celebrated the world’s first self-amplifying mRNA vaccine approval from CSL and Arcturus Therapeutics, and huge investments such as the $270 million raised by Orbital Therapeutics, the field of next generation RNA therapeutics emerged as a preferred RNA platform, with circular RNA, self-amplifying RNA and transfer RNA offering potential for improved stability, longevity, and increased therapeutic potential.
The 3rd Next Generation RNA Therapeutics Summit will return to Boston in 2025 to cover the depth and breadth of circular RNA, self-amplifying RNA (saRNA) and transfer RNA, from discovery to clinic and towards scalable manufacturing, equipping RNA leaders with strategic insights to fast-track these therapies into the clinic unlocking the huge therapeutic and commercial potential of this emerging class of medicines.
FULL AGENDA 2024
In 2024, leading minds of the field, including representatives from Replicate Bioscience, Sail Biomedicines, Johnson & Johnson, Pfizer, Orbital Therapeutics, and more explored accelerating discovery, development, and manufacturing of safe and effective next generation RNA therapeutics with significant advantages over the traditional therapies to treat previously “incurable” diseases with unmet needs.
A Snapshot of the 2024 World-Class Speaker Faculty:
Rachel Groppo
Director, Self-Amplifying RNA Team Lead
The Janssen Pharmaceutical Companies of Johnson & Johnson
What You Missed:
Investigate the most recent advancements and technologies in Self-Amplifying RNA therapeutics, focusing on enhancing manufacturing and analysis capabilities to elevate patient treatment outcomes and produce successful RNA medicines with high quality, traceability, & reliability with case studies from Replicate Bioscience, Johnson & Johnson, and Strand Therapeutics
Explore the latest research findings on circular RNA and pinpoint the primary hurdles including improving yield, purity, and scalability in the manufacturing and analytics of circular RNA to increase clinical success of circular RNAs towards patients with invaluable insights from industry leaders at Orbital Therapeutics, Sail Biomedicines, & NoctuRNA Therapeutics
Unlock the widespread potential of circular RNA, transfer RNA and self-amplifying RNA therapeutics with improved sequence design, target selection and in vivo delivery to treat previously “incurable” diseases with unmet needs with insights from Atomic AI & Sanofi
Address the importance of collaboration and investment in advancing pharma and biotech innovations, and discuss the strategies for mitigating risks and maximizing returns on investment with investor insights from Rothwell Figg as well as John Hopkins University & Capstan Therapeutics
Engage in an in-depth discussion regarding the ongoing immunogenicity studies aimed at mitigating off-target effects and evaluating the safety and efficacy of your of circular RNA, transfer RNA and self-amplifying RNA therapeutics. Explore the different strategies to ensure the optimal performance and safety profile of cutting-edge RNA with insights from Pfizer & Sanofi
Who Attended This Meeting?
Official 2024 Partners
Other Events in the World RNA Series
